OFFICE OF THE GOVERNOR

SEP 28 2024

To the Members of the California State Assembly:

I am returning Assembly Bill 2467 without my signature.

This bill would require health plans to cover the costs of evaluation and treatment options for perimenopause and menopause, without utilization review, and require this coverage to include at least one option in each formulation of specified perimenopause and menopause treatments. Health plans would also be required to provide clinical care recommendations for hormone therapy to contracted primary care providers annually.

I appreciate the author's intent to ensure access to comprehensive and up-to-date treatment of perimenopause and menopause. However, this bill's expansive coverage mandate in conjunction with a prohibition on utilization management (UM) is too far-reaching. Health plans use UM to ensure enrollees receive the right care at the right time, which is especially important when there are new and emerging treatments. Further, a mandate to cover non-FDA approved treatments, without UM, is unprecedented. These factors, in conjunction with ambiguities in the bill for undefined terms, raise concerns for cost containment and bill implementation.

I encourage the Legislature and stakeholders to continue to work towards a more tailored solution that can improve access to perimenopause and menopause care, inform patients of their options, and encourage providers to stay informed of the latest clinical care recommendations.

For these reasons, I cannot sign this bill.

Sincerely,



Gavin Newsom